GPT and metabolic dysfunction-associated steatotic liver disease: As shown in Table 1, it was found that the levels of TC, TG, ALT, and AST were declined in NAFLD patients treated with DHZCPs, which were lower than those in untreated NAFLD patients (P < 0.05).